Shin-Etsu Chemical Has Developed a New Volatile Silicone Fluid for Personal Care
Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh) has developed a new type of volatile silicone fluid, the “KF-4422.”
Volatile silicone fluids are essential components that are being used in the development of diverse personal care products, including skin care, make-up and sunscreen products. This product will enhance the sensory feeling of users of various personal care products, at the same time, by combined use with silicone-based film formers, it can add a high water- resistant property.
KF-4422, the newly developed product, is a high-purity volatile silicone fluid that was developed by replacing a part of a methyl group with an ethyl group in the molecular structure of dimethyl silicone fluid (INCI name: dimethicone). Because it possesses volatility, it provides a light and smooth sensory feel for end-users, which is a special feature of this silicone fluid, and its volatile rate is located in-between that of the existing KF-995 and KF-96L-2CS silicone fluids.
Furthermore, compared with existing products, the new product features superior solubility with such materials as hydrocarbons and UV absorbers. In the development of personal care products, when endeavoring to enhance sensory use, a delicate difference in feeling is sought after, and thus we expect that the development of this new product and its introduction on the market will lead to a strong positive customer response as a result of meeting their requests.
Shin-Etsu offers a very wide range of silicone products, including silicone fluids, silicone emulsions, silicone gels and silicone powders. Moreover, because they are multifunctional and excellent in safety, they have become essential cosmetic ingredients in the formulations of various personal care products with an emphasis on high functionality and high quality.
Taking advantage of Shin-Etsu Chemical’s superior product quality and technological strengths as well as our system for detailed response to our customers' requests, going forward Shin-Etsu will continue to strive to meet the needs of the diversifying market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210516005050/en/
Contact information
For inquiries about this matter, please contact:
Shin-Etsu Chemical Co., Ltd. Public Relations Dept. Tetsuya Koishikawa
TEL: 03-3246-5091, or from outside Japan: 81-3-3246-5091
FAX: 03-3246-5096, or from outside Japan: 81-3-3246-5096
e-mail: sec-pr@shinetsu.jp
www.shinetsu.co.jp
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mundipharma and Vectura announce plans to reformulate flutiform ® (fluticasone propionate/formoterol fumarate) pressurised metered-dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint16.4.2024 11:00:00 CEST | Press release
Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416962162/en/ The productis an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of a combination product is appropriate, and has been available on the market for more than a decade.3 It currently uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant.3 European Union regulation on these types of gases aims to reduce their use, and therefore their emissions, by two-thirds by 2030.1 Work is already under way to source an alternative
Caranx Medical announces successful world first robotic assisted transcatheter heart valve implantation in an animal16.4.2024 10:30:00 CEST | Press release
Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal. The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Caranx CMO Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team. “This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients' lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx. “This major medical first lies not only in the technical achievement of Caranx Medical's engine
Arthur D. Little Publishes Human After All – Latest Edition of PRISM Magazine16.4.2024 10:00:00 CEST | Press release
Arthur D. Little (ADL) has published Human After All – the latest edition of its strategy and innovation magazine PRISM. As we enter the era of AI, the first edition of 2024 highlights the importance of taking a human-centric approach to business management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416226137/en/ Arthur D. Little has published Human After All – the latest edition of its strategy and innovation magazine PRISM. (Graphic: Business Wire) The magazine features seven key articles: Optimistic global CEOs focus on people and skills in an AI future - Our lead article shares highlights from the ADL 2024 CEO Insights Study, finding that CEOs are increasingly confident of future economic success. The people-centric lab of the future – how technology and AI can play a key role in driving breakthrough innovation by enabling people to become perfect innovators. The future workforce - Recruiting and retaining vital
Magnesium Capital closes oversubscribed inaugural Fund at €135m hard cap16.4.2024 09:32:00 CEST | Press release
Magnesium Capital, the Energy Transition buyout specialist, is delighted to announce the successful close of its inaugural Fund, Magnesium Capital I, at its hard cap of €135m, exceeding the €100m Fund target. The final close occurred less than a year after the Fund’s first close with Magnesium attracting blue-clip institutional investors from the US, Europe and the UK. Magnesium focuses on profitable European companies with proven technologies or tech-enabled services that are positively impacting the decarbonisation of the production, distribution and consumption of energy. The team has been backing the buyouts of such businesses for a number of years on a direct deal basis. Since inception, Magnesium has completed seven platform investments, signed six follow-on acquisitions and exited two investments for 4.2x gross MOIC. The combined impact of these portfolio companies already directly contributes to the avoidance of over 30 million tonnes of CO2 equivalent per annum. Ian Jones, Man
MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH00216.4.2024 09:00:00 CEST | Press release
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. MRM Health’s MH002-PC-201 study was a multi-center, open-label clinical trial in 14 acute Pouchitis (PC) patients at multiple clinical sites in Belgium and Italy. The study was designed to evaluate safety (primary objective), initial efficacy, and mechanistic effects of MH002 over 8 weeks. More information about the trial is available at clinicaltrialsregister.eu. The trial met its primary objective with an excellent safety and tolerability at a fixed dose of 400mg per day over 8 weeks’ administration. Treatment-Emergent Adverse Events (TEAE) reported were predominantly mild and unrelated, and there was no evidence of adverse reactions related to MH002. It also demonstrated initial efficacy in clinically relevant parameters,